(8S,11R,13S,14S,17S)-11-[4-[(E)-羟基亚氨甲基]苯基]-17-甲氧基-17-(甲氧基甲基)-13-甲基-1,2,6,7,8,11,12,14,15,16-十氢环戊烯并[a]菲-3-酮 | 199396-76-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (8S,11R,13S,14S,17S)-11-[4-[(E)-羟基亚氨甲基]苯基]-17-甲氧基-17-(甲氧基甲基)-13-甲基-1,2,6,7,8,11,12,14,15,16-十氢环戊烯并[a]菲-3-酮
• 中文别名: 羽扇烷-28-酸,3-(乙酰氧基)-,甲基酯,(3b)-(9CI)
• 英文名称: asoprisnil
• 英文别名: asoprosnil；J-867；11β-[4-(hydroxyiminomethyl)phenyl]-17β-methoxy-17α-(methoxymethyl)estra-4,9-dien-3-one；(8S,11R,13S,14S,17S)-11-[4-[(E)-hydroxyiminomethyl]phenyl]-17-methoxy-17-(methoxymethyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
• CAS: 199396-76-4
• 化学式: C₂₈H₃₅NO₄
• 分子量: 449.59
• InChiKey: GJMNAFGEUJBOCE-MEQIQULJSA-N

物化性质

• 熔点：
  118° (dec)
• 比旋光度：
  D +197° (CHCl3)
• 沸点：
  602.0±55.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  5

制备方法与用途

生物活性

Asoprisnil（J867）是一种选择性孕激素受体调节剂，在动物和人类的各种孕酮靶向组织中表现出混合的孕酮激动剂和拮抗剂作用。

反应信息

• 作为反应物：
  描述：

  (8S,11R,13S,14S,17S)-11-[4-[(E)-羟基亚氨甲基]苯基]-17-甲氧基-17-(甲氧基甲基)-13-甲基-1,2,6,7,8,11,12,14,15,16-十氢环戊烯并[a]菲-3-酮 在 盐酸 、 聚合甲醛 、 三氟化硼乙醚 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 21.0h， 生成 4-[3,3-Ethylendithio-17β-methoxy-17α-(methoxymethyl)-estra-4,9-dien-11β-yl]benzaldehyd
  参考文献：
  名称：

  Schubert; Menzer; Undeutsch, Pharmazie, 2000, vol. 55, # 6, p. 463 - 464

  摘要：

  DOI：
• 作为产物：
  描述：

  4-[17β-methoxy-17α(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]-benzaldehyde 在 吡啶 、 盐酸羟胺 、 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 (8S,11R,13S,14S,17S)-11-[4-[(E)-羟基亚氨甲基]苯基]-17-甲氧基-17-(甲氧基甲基)-13-甲基-1,2,6,7,8,11,12,14,15,16-十氢环戊烯并[a]菲-3-酮
  参考文献：
  名称：

  Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)

  摘要：

  本发明涉及一种在试验和生产规模上可靠且可重复制备4-[17β-甲氧基-17α-甲氧甲基-3-氧基雌二烯-4,9-二烯-11β-基]苯甲醛(E)-肟(asoprisnil)的方法。通过这种方法制备的asoprisnil具有很好的物理稳定性，因此特别适用于固体制药形式（片剂、包衣片剂等）的制造。

  公开号：

  US20090054387A1

文献信息

• [EN] AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS<br/>[FR] AMIDOIMIDAZOPYRIDAZINES À TITRE D'INHIBITEURS DE KINASES MKNK-1
  申请人：BAYER PHARMA AG

  公开号：WO2014118135A1

  公开（公告）日：2014-08-07

  The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的酰胺取代咪唑吡啶化合物，其中A、R1、R2、R3、R4和n如权利要求中所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。
• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• [EN] AMINOIMIDAZOPYRIDAZINES<br/>[FR] AMINOIMIDAZOPYRIDAZINES
  申请人：BAYER PHARMA AG

  公开号：WO2014076162A1

  公开（公告）日：2014-05-22

  The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的氨基取代咪唑吡啶化合物，其中A、R1、R2、R3、R4和n如权利要求中所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用时，用于治疗或预防过度增殖和/或血管生成障碍的疾病。
• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。